Zacks Research Issues Pessimistic Forecast for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Investment analysts at Zacks Research reduced their FY2026 EPS estimates for shares of Bristol Myers Squibb in a research report issued to clients and investors on Wednesday, November 11th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $6.44 for the year, down from their previous estimate of $6.86. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.46 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q4 2026 earnings at $1.47 EPS, Q2 2027 earnings at $1.70 EPS, Q4 2027 earnings at $1.56 EPS and FY2028 earnings at $4.77 EPS.

Other equities research analysts have also recently issued reports about the company. Raymond James Financial initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 13th. Wells Fargo & Company decreased their target price on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 13th. Finally, Daiwa Securities Group upped their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $65.46.

Bristol Myers Squibb Trading Down 0.8%

NYSE BMY opened at $62.42 on Friday. Bristol Myers Squibb has a 1-year low of $45.26 and a 1-year high of $68.64. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. The stock has a 50-day moving average of $61.99 and a 200-day moving average of $60.27. The firm has a market cap of $127.58 billion, a PE ratio of 13.84, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. During the same quarter last year, the company earned $1.63 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were issued a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb’s payout ratio is 55.88%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julia Haller sold 3,800 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of institutional investors have recently bought and sold shares of BMY. Lazard Asset Management LLC grew its holdings in Bristol Myers Squibb by 23.7% in the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after purchasing an additional 368,193 shares during the period. Callan Family Office LLC bought a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $3,575,000. Saudi Central Bank lifted its holdings in shares of Bristol Myers Squibb by 90.2% during the second quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock valued at $8,235,000 after purchasing an additional 67,780 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of Bristol Myers Squibb by 17.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock worth $123,465,000 after purchasing an additional 317,360 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Recent Bristol Myers Squibb Headlines

Here are a few of the latest headlines about BMY:

• Positive Sentiment: Some analysts and commentators consider BMY attractively valued, citing roughly 10 times forward earnings and a view that shares remain below fair value despite a strong multi-year run. That could support investor interest if the company delivers on its cash-flow and pipeline prospects. Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare. Bristol Myers Squibb Stock Looks Below Fair Value Following A 41% Run
• Neutral Sentiment: Bristol Myers plans to bring its scientific and clinical teams together in a unified R&D organization, aiming to accelerate development and make better use of new technologies. Research chief Robert Plenge is leaving as part of the change. The strategy could improve productivity, but the leadership transition and results of the restructuring remain uncertain. Bristol Myers to merge scientific, clinical teams under new R&D structure Bristol Myers research chief to depart in evolution of company’s structure
• Negative Sentiment: Drug-price negotiations are a potential longer-term headwind for BMY, with the article describing the company as facing a bigger test in the years ahead. The risk is not presented as an immediate revenue hit, but could weigh on future pricing and growth expectations. Drug pricing risks for pharmaceutical companies

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.